Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme

INTRODUCTION: In January 2013 a novel type of multicomponent protein-based vaccine against group B meningococcal disease was licensed by the European Medicines Agency. With the widespread use of the meningococcal serogroup C conjugate vaccines, serogroup B remains now the major cause of bacterial me...

Descripción completa

Detalles Bibliográficos
Autores principales: Tirani, Marcello, Meregaglia, Michela, Melegaro, Alessia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395261/
https://www.ncbi.nlm.nih.gov/pubmed/25874805
http://dx.doi.org/10.1371/journal.pone.0123383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395261/
https://www.ncbi.nlm.nih.gov/pubmed/25874805
http://dx.doi.org/10.1371/journal.pone.0123383

Ejemplares similares